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Abstract 26 
 27 
The knowledge of genetic variants shaping human placental transcriptome is limited and they are 28 
not catalogued in the Genotype-Tissue Expression project. So far, only one whole genome analysis 29 
of placental expression quantitative trait loci (eQTLs) has been published by Peng et al. (2017) with 30 
no external independent validation. We report the second study on the landscape of placental 31 
eQTLs. The study aimed to generate a high-confidence list of placental cis-eQTLs and to 32 
investigate their potential functional implications. Analysis of cis-eQTLs (±100 kbp from the gene) 33 
utilized 40 placental RNA sequencing and respective whole genome genotyping datasets. The 34 
identified 199 placental cis-eSNPs represented 88 independent eQTL signals (FDR <5%). The most 35 
significant placental eQTLs (FDR<10-5) modulated the expression of ribosomal protein RPL9, 36 
transcription factor ZSCAN9 and aminopeptidase ERAP2. The analysis confirmed 50 eSNP-37 
eGenes pairs reported by Peng et al. (2017) and thus, can be claimed as robust placental eQTL 38 
signals. The study identified also 13 novel placental eGenes. Among these, ZSCAN9 is modulated 39 
by several eSNPs (experimentally validated: rs1150707) that have been also shown to affect the 40 
methylation level of genes variably escaping X-chromosomal inactivation. The identified 63 41 
placental eGenes exhibited mostly mixed or ubiquitous expression. Functional enrichment analysis 42 
highlighted 35 GO categories with the top ranking pathways “ruffle membrane” (FDR = 1.81×10-43 
2) contributing to the formation of motile cell surface and “ATPase activity, coupled” (FDR = 44 
2.88×10-2), critical for the membrane transport. Placental eGenes were also significantly enriched 45 
in pathways implicated in development, signaling and immune function. However, this study was 46 
not able to confirm a significant overrepresentation of GWAS top hits among the placental eSNP 47 
and eGenes, reported by Peng et al., 2017. The identified eSNPs were further analyzed in 48 
association with newborn and pregnancy traits. In the discovery step, a suggestive association was 49 
detected between the eQTL of ALPG (rs11678251) and reduced placental, newborn’s and infant’s 50 
weight. Meta-analysis across REPROMETA, HAPPY PREGNANCY, ALSPAC cohorts (n=6,830) 51 
did not replicate these findings. In summary, the study emphasizes the role of genetic variation in 52 
driving the transcriptome profile of the human placenta and the importance to explore further its 53 
functional implications. 54 
 55 
  56 
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Introduction 57 
The placenta is a unique mammal-specific organ. It serves the developing fetus during its short 58 
intrauterine period not only as a mediator of maternal resources, but also as a contributor to its 59 
developmental programming, growth and maturation for the postnatal life. Throughout its restricted 60 
lifetime, coordinated dynamics of placental gene expression across the entire gestation reflects the 61 
growing needs of the fetus in order to guarantee the normal course of pregnancy (Uusküla et al., 62 
2012; Winn et al., 2007). Disturbances in placental gene expression at any gestational time point 63 
may lead to or reflect placental malfunction and various pregnancy-related complications of the 64 
mother and/or the fetus, such as recurrent pregnancy loss, preeclampsia, intra-uterine growth 65 
restriction (Sõber et al., 2015, 2016).  66 
Several modulators of placental gene expression have been investigated in order to uncover their 67 
role in placental function and in predisposition to develop pregnancy complications. Amongst the 68 
most studied effectors are disturbances in intrauterine conditions (e.g. hypoxia (Soares et al., 69 
2017)), communication at the maternal-fetal interface (Pavličev et al., 2017), placental microRNAs 70 
(Deshpande and Balasinor, 2018) and epigenetic alterations modulating the transcriptional activity 71 
of critical placental genes (Deshpande and Balasinor, 2018). Additional intrinsic genomic factors 72 
determining the expression level of one or many genes are expression quantitative loci (eQTLs), 73 
alternatively referred as eSNPs. Based on the analysis of 48 different human tissues in the 74 
framework of the Genotype-Tissue Expression (GTEx) project – the largest coordinated activity 75 
aiming to uncover the relationship between genetic variation and gene expression (Ardlie et al., 76 
2015; Lonsdale et al., 2013), the number of eSNPs across the human genome has been estimated to 77 
exceed 150,000 (Aguet et al., 2017). The contribution of eSNPs to human pathological conditions 78 
has been shown directly in numerous targeted studies (e.g. breast (Li et al., 2013) and pancreatic 79 
cancer (Zhang et al., 2018), nephrotic syndrome (Gillies et al., 2018)) and indirectly via enrichment 80 
of eSNPs among top associated loci in GWA studies of various diseases and traits, such as psoriasis 81 
(Ding et al., 2010) and height (Yengo et al., 2018). As the GTEx project is based on the analysis of 82 
donated post-mortem tissues, it does not contain any placental samples. However, it is well 83 
acknowledged that eSNPs vary across different tissues (Grundberg et al., 2012; McKenzie et al., 84 
2014) and even as much as 12-40% of them have been estimated to be tissue-specific (Gillies et al., 85 
2018; Zhang et al., 2018). Therefore, it is critical to uncover placental eSNPs in order to understand 86 
their role in modulating placental function and risk to gestational disturbances. 87 
Until recently, studies of human placental eSNPs have been restricted to reports focusing on 88 
variants modulating transcript levels of single placental genes and their effect on pregnancy 89 
outcomes. Of the few studies on placental eQTLs, one has linked variants in FKBP5 with infant 90 
neurobehavioral phenotypes (Paquette et al., 2014), and another reported an association between 91 
STC1 eSNPs and preeclampsia (Juhanson et al., 2016). The only published large-scale placental 92 
eQTL study demonstrated that the majority of placental eSNPs are located in the vicinity of the 93 
modulated genes (eGenes) (Peng et al., 2017). Analysis of 159 placental transcriptomes identified 94 
3218 (98.9%) eSNPs with cis-, but only 35 (1.1%) variants with significant trans-effects on the 95 
expression of affected genes. The study also demonstrated that >5% of all unique loci associated 96 
with any disease in genome-wide association studies (GWAS) represented placental eSNPs. The 97 
potential role of placental transcriptome profile in ‘(mis)programming’ the offspring’s risks to 98 
human late-onset common diseases was previously discussed in the context of a substantial overlap 99 
between GWAS top loci and genes exhibiting high mid-gestational placental expression (Uusküla 100 
et al., 2012). 101 
The current study aimed to generate a high-confidence list of genetic variants modulating placental 102 
gene expression. The analysis confirmed 50 eSNP-eGenes pairs reported recently by Peng et al., 103 
2017 and identified 13 novel placental eGenes. The variants were further explored for their potential 104 
link to complex diseases and newborn growth parameters. 105 
 106 
  107 
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Materials and methods 108 
 109 
Ethics statement 110 
The REPROgrammed fetal and/or maternal METAbolism (REPROMETA) and HAPPY 111 
PREGNANCY (full study name “"Development of novel non-invasive biomarkers for fertility and 112 
healthy pregnancy") studies were approved by the Ethics Review Committee of Human Research 113 
of the University of Tartu, Estonia (permissions no 146/18, 27.02.2006; 150/33, 18.06.2006; 114 
158/80, 26.03.2007; 221/T-6, 17.12.2012; 286/M-18, 15.10.2018). All study participants were 115 
recruited, and the study material was collected at the Women’s Clinic of Tartu University Hospital, 116 
Estonia in 2006–2011 (REPROMETA) and in 2013-2015 (HAPPY PREGNANCY). All 117 
participants in the REPROMETA and HAPPY PREGNANCY studies were of white European 118 
ancestry and living in Estonia. A written informed consent to participate in the study was obtained 119 
from each individual prior to recruitment. 120 
Ethical approval for the Avon Longitudinal Study of Parents and Children (ALSPAC) was obtained 121 
from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. The 122 
study recruited pregnant women in Bristol area, United Kingdom in 1991-1992 123 
(http://www.alspac.bris.ac.uk). Consent for biological samples was collected in accordance with 124 
the Human Tissue Act (2004). Informed consent for the use of data collected via questionnaires and 125 
clinics was obtained from participants following the recommendations of the ALSPAC Ethics and 126 
Law Committee.  127 
All procedures and methods in the three studies have been carried out in compliance with the 128 
guidelines of the Declaration of Helsinki. 129 
 130 
REPROMETA dataset for the discovery placental eQTL analysis 131 
The REPROMETA study represents family trios (mother, father, placenta) recruited before or 132 
shortly after delivery of a singleton newborn at the Women’s Clinic of Tartu University Hospital, 133 
Estonia. The study was designed to include well-defined, clinically diagnosed diverse scenarios of 134 
pregnancy outcomes at term (gestational age 36-42 weeks). The full REPROMETA placental 135 
sample set analyzed in the current study (n=336) is comprised of five clinical subgroups: delivery 136 
of a small-for-gestational-age (SGA, birth weight <10th centile (Sildver et al., 2015); n=65) or large-137 
for-gestational-age newborn (LGA, >90th centile; n=83), cases of maternal gestational diabetes 138 
(GD; n=41) or severe late-onset preeclampsia (PE; n=43), and healthy term pregnancies (birth 139 
weight 10th-90th centile; n=104). Criteria for the clinical subgrouping are detailed in 140 
Supplementary Methods. Clinical and epidemiologic data of the mother and the newborn were 141 
collected from medical records.  142 
The current eQTL discovery study utilized previously published RNA sequencing (RNA-Seq) 143 
(Reiman et al., 2017; Sõber et al., 2015), and corresponding genome-wide genotyping datasets of 144 
40 term placental samples (Kasak et al., 2015), where each REPROMETA subgroup (NORM, PE, 145 
GD, SGA, LGA) was represented by eight placental transcriptomes maximally matched for the 146 
gestational age, delivery mode and proportions of male/female newborns (Table 1). Placental 147 
sampling, RNA extraction, library sequencing and basic informatics are detailed in the 148 
Supplementary Methods and in (Reiman et al., 2017; Sõber et al., 2015).  149 
Genome-wide genotyping of the same placental samples was carried out on Illumina 150 
HumanOmniExpress-12-v1 BeadChip (>733,000 SNPs, median spacing 2.1 kb) (Kasak et al., 151 
2015). Samples were genotyped with an average overall call rate >99% per individual per genotype.  152 
We excluded SNPs if they deviated from Hardy-Weinberg Equilibrium (HWE) (P < 1×10−6) or had 153 
no minor allele carriers in our dataset. In total of 661,354 genotyped SNPs were taken forward to 154 
the next step.  155 
 156 
Bioinformatics for eQTL detection  157 
The initial unfiltered RNA-Seq dataset of 40 placental samples (Reiman et al., 2017; Sõber et al., 158 
2015) included gene expression data for 53,893 genes (Ensembl v67, 159 
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http://www.ensembl.org/index.html). Gene expression was quantified using htseq-count (as raw 160 
read counts) and then normalized for read depth of the sample. Genes with low expression (applied 161 
empirical cutoff: median expression <100 normalized read counts) were excluded. After further 162 
filtering out mitochondrial genes, 11,733 genes were retained for the eQTL analysis (Fig. S1). 163 
As a very low number of placental trans-eQTLs was expected (Peng et al., 2017) and the chance to 164 
detect spurious trans-eQTL associations is high (Yao et al., 2017), our study design focused on cis-165 
eQTL discovery to maximize true-positive, functionally relevant findings. In the current study, we 166 
defined cis-SNPs to locate within ±100 kbp from the gene start/end coordinates as these regions 167 
have high probability of containing significant and functionally relevant eQTL hits (Veyrieras et 168 
al., 2008). SNP and gene coordinates were extracted from the Ensembl database using BioMart 169 
(Ensembl v54) and cis-eQTL testing was implemented in Matrix eQTL package for R (Shabalin, 170 
2012). The final number of SNP included into eQTL testing was 353,599 and the total number of 171 
performed tests was 659,826 (Data 1). Association between gene expression level (quantified as 172 
normalized read counts) and cis-SNPs was carried out using linear regression adjusted by the 173 
pregnancy outcome (normal term or PE, GD, SGA, LGA pregnancy), labor activity and newborn 174 
sex. Nominal P-values were corrected for multiple testing using a built-in Benjamini and Hochberg 175 
FDR method in Matrix eQTL. A statistically significant eSNP-eGene association was defined as 176 
FDR<0.05. For each identified eQTL, the proportion of gene expression variability explained by 177 
the SNP was calculated (R2).  178 
eSNPs were clustered into high LD-groups (r2>0.8) and only the empirically selected lead SNP 179 
with the lowest p-value was taken forward to represent the LD-group in subsequent analyses. For 180 
determining the top eGenes, the lowest P-value of any associated eSNP was considered as the P-181 
value for the gene. 182 
eGenes were analyzed for the functional enrichment among Gene Ontology pathways (Biologial 183 
processes, Cellular Components, Molecular functions). The statistical significance testing of the 184 
enrichment was implemented in FUMA (http://fuma.ctglab.nl/, Watanabe et al., 2017) and FDR 185 
was estimated using Benjamini-Hochberg correction for multiple testing. GWAS data was 186 
downloaded from GWAS Catalog (https://www.ebi.ac.uk/gwas/docs/file-downloads, all 187 
associations v1.0_e91). SNPnexus (Dayem Ullah et al., 2018) was used to determine the closest 188 
gene for each GWAS hit. χ-square test was used to determine enrichment of eGenes and eSNPs 189 
among GWAS results.  190 
 191 
Taqman RT-qPCR validation of cis-eQTLs in REPROMETA placental samples 192 
Experimental validation of the discovery study targeted protein coding genes with multiple 193 
identified cis-SNPs that exhibited low FDR and at least two-fold gene expression difference 194 
between the placentas with heterozygote and major homozygote genotypes. The cis-eSNPs selected 195 
for the validation were rs1150707 (ZSCAN9 c.568+1990 C>T); rs10044354 (ERAP2 g.96984791 196 
C>T) and rs11678251 (ALPG c.-318 G>A). For these SNPs, an extended REPROMETA placental 197 
sample set (n=336; Table 2) was genotyped using Sequenom iPLEX Gold genotyping system 198 
(Sequenom, Agena, USA). Primers are provided in Table S1. Based on the genotyping outcome, 199 
24 placentas per each eSNP were selected for the Taqman RT-qPCR gene expression quantification 200 
(Table S2). Taqman RT-qPCR and testing of eQTL effects targeted also three neighboring genes 201 
(ALPP, ERAP1, LNPEP). 202 
 eQTL testing was conducted as previously, except for using gestational age as an additional 203 
cofactor to account for the wider range of gestational age in validation samples. The expression 204 
levels for all samples were transformed to represent the fold-change from the median expression of 205 
major homozygotes used as the reference. Details for Taqman RT-qPCR validation are provided in 206 
Supplementary Methods and Table S3. 207 
 208 
HAPPY PREGNANCY and ALSPAC pregnancy cohorts and data 209 
The HAPPY PREGNANCY study recruited prospectively 2,334 pregnant women during their first 210 
antenatal visit to Women’s Clinic of Tartu University Hospital, Estonia. Longitudinal clinical and 211 
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epidemiological data includes reproductive history, parental lifestyle, the course and outcome of 212 
pregnancy. The current study analyzed 408 placental samples with a specific focus on SGA 213 
newborns (n=158; Table 2). 214 
The Avon Longitudinal Study of Parents and Children (ALSPAC) initially recruited 14,541 215 
pregnant women resident in Avon, United Kingdom, with expected dates of delivery 1st April 1991 216 
to 31st December 1992 (Boyd et al., 2013; Fraser et al., 2013). For all recruited cases medical data 217 
from obstetric and perinatal records were documented. From the initial pregnancies, 14,062 resulted 218 
in live births. Gestational age at the delivery was recorded the nearest gestational week. The current 219 
study analyzed 7669 newborns with available genotype data (Table 2). Please note that the 220 
ALSPAC study website contains details of all the data that are available through a fully searchable 221 
data dictionary and variable search tool: http://www.bristol.ac.uk/alspac/researchers/our-data/. 222 
The HAPPY PREGNANCY placental samples were genotyped for the rs11678251 (ALPG c.-318 223 
G>A) using a pre-made Taqman assay (ID C__27838320_10, Applied Biosystems, Foster City, 224 
USA). For the ALSPAC cohort, genotypes of the proxy SNP rs744873 (r2=1.0 with rs11678251) 225 
were obtained from the genome-wide array dataset(Boyd et al., 2013). 226 
 227 
Genetic association testing 228 
Genetic association analysis was implemented in PLINK, ver. 1.09 (Purcell et al., 2007) 229 
(http://pngu.mgh.harvard.edu/~purcell/plink/). Differences in allelic distributions between term 230 
cases of normal pregnancy and gestational complications (PE, GD, SGA, LGA) in the discovery 231 
REPROMETA sample set was assessed using logistic regression (additive genetic model). 232 
Genetic association tests with newborn parameters applied linear regression analysis. The 233 
REPROMETA placental genotypes (n=336) for three cis-eQTLs rs1150707 (ZSCAN9 c.568+1990 234 
C>T), rs10044354 (ERAP2 g.96984791 C>T) and rs11678251 (ALPG, c.-318 G>A) were tested in 235 
association with birth weight and length, placental weight, newborns’ head and chest circumference 236 
and postnatal growth (Table S4). The tests with the birth parameters were implemented under 237 
additive and recessive models, adjusted to newborn sex and gestational age (in days). Based on the 238 
outcome of the association testing with birth parameters, only the sex-adjusted recessive model was 239 
applied in further association analysis with infant postnatal growth. Infant height and weight had 240 
been documented at 6 (n=233) and 12 (n=216) months of age (Table S5). For prematurely born 241 
children (<259 g. days) postnatal growth was adjusted to the gestational age at birth 242 
(Supplementary Methods). 243 
Suggestive association of the ALPG c.-318 G>A (rs11678251) with the newborn growth parameters 244 
in the REPROMETA study (under recessive model) was further assessed in independent cohorts 245 
HAPPY PREGNANCY (n=408; Estonia) and ALSPAC (n=7669; UK). For ALSPAC a proxy SNP 246 
rs744873 was analyzed. The test results of individual REPROMETA, HAPPY PREGNANCY and 247 
ALSPAC studies were combined in a meta-analysis under fixed effects model. 248 
The obtained nominal P-values <0.05 were considered as suggestive association. The Bonferroni 249 
corrected statistical significance level was estimated P<1.2×10-3 for the 42 tests in the initial 250 
REPROMETA study and P<3.6×10-3 for the 14 tests in the meta-analysis, respectively. 251 
 252 
Results  253 
Discovery analysis of placental expression quantitative trait loci (eQTL) 254 
Discovery analysis of the placental eQTLs was implemented using published RNA sequencing 255 
(Sõber et al., 2015) and whole genome genotyping (Kasak et al., 2015) datasets representing 40 256 
unrelated term placentas collected during the REPROMETA study and representing a diverse range 257 
of pregnancy outcomes (Table 1). The analysis design targeted cis-eQTLs (±100 kbp from gene) 258 
and included genes with sufficient transcript levels (>100 reads; n=11,733 genes after filtering) in 259 
order to avoid spurious associations (Figure S1). Linear regression testing with 353,599 SNPs 260 
(Illumina HumanOmniExpress array) identified 199 placental cis-eSNPs corresponding to the 261 
applied stringent statistical significance threshold (FDR <5%) (Figure 1A, Table S6A, Data 1). 262 
The proportion of gene expression explained by the identified eQTLs (R2) varied from 0.45 to 0.77 263 
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(mean R2 = 0.52) (Figure 1B). When taking into account linkage disequilibrium (LD; r2 > 0.8) 264 
between the eSNPs, there were in total 88 independent cis-eQTL association signals representing 265 
47 singleton eSNPs and 41 eSNP-clusters localized across the genome, except for some smaller 266 
chromosomes (#18, 20, 21, Y; Figure S2). The densest coverage of independent eSNPs-eGene 267 
pairs was detected on chromosome 19 (n=10 SNPs, 0.16 SNP/Mbp; n=6 genes, 0.09 gene/Mbp), 268 
the most gene-rich chromosome in the human genome (Venter et al., 2001) (Table S7). The highest 269 
number of eSNPs (23, including seven independent signals) was mapped for the ZSCAN9 gene that 270 
has a potential function in the X-chromosome inactivation process (Luijk et al., 2018) (Table S6A).  271 
The associated eSNPs modulated the expression level of 63 eGenes expressed moderate to high in 272 
the human placenta (Table S6A-B, Figure 1C). The most significant placental eQTLs (FDR<10-5) 273 
with a positive minor allele effect were modulating the expression of genes encoding the ribosomal 274 
protein RPL9 [fold change, fc(het) = 1.64, fc(min hom) = 2.32], the transcription factor ZSCAN9 275 
[fc(het) = 3.62, fc(min hom) = 4.54] and the aminopeptidase ERAP2 [fc(het) = 3.22, fc(min hom) 276 
= 4.65] (Table 3). In the literature, genetic variants around ERAP2 have been associated with 277 
autoimmunity related disorders, whereas the ZSCAN9 gene is surrounded by the risk variants for 278 
neuropsychiatric diseases and cancer (Figure 2A-B). 279 
The largest eSNP effect was detected for the phospholipid transporter ATP8A1 transcript levels 280 
[FDR = 7.44×10-4; fc(het) = 4.64, fc(min hom) = 7.92]. Overall, the number of eQTLs with a 281 
positive effect on gene expression was twice as many compared to those with a negative effect. Top 282 
eQTLs exhibiting negative minor allele effect were associated with the expression of DDX11, 283 
PLEKHG1 and THNSL2 implicated in fetal development, signaling and cellular proliferation, 284 
respectively (Table 3). Nearly 80% of the identified eGenes (n=50) overlapped with the gene list 285 
reported by Peng et al. (Figure 1D). Despite the differences in the study design, ten of the 63 286 
identified placental eGenes in our dataset fall within 1% and 45 genes within 25% of the loci with 287 
the lowest P-value in the previous independent dataset (Peng et al., 2017) (Table S6B-C). As an 288 
added value we identified 13 novel placental eGenes (10 protein coding, 3 pseudogenes), including 289 
nine associations that were supported by the GTEx data in other tissues (Table 4). Amongst these, 290 
the identified eQTLs for the genes ZSCAN9 and TLDC1 were ranked within the top 10 gene 291 
expression associated variants in our analysis (Table 3). The expression level of RBPJ, TCIM, 292 
TPRN and THUMPD2 was associated with potential placenta specific eQTLs that have not been 293 
detected in the GTEx project. 294 
 295 
Placental eQTLs and risk to term pregnancy complications 296 
In the discovery sample, none of the placental eQTLs were significantly associated with adverse 297 
pregnancy outcomes at term after applying multiple testing correction (Table S6D). Among 298 
nominal suggestive associations a substantial effect of ZSCAN9 eSNP (rs1150707) was detected to 299 
the risk of gestational diabetes (GD) (logistic regression; OR = 21, P = 0.02) or the birth of a small-300 
for-gestational-age newborn (SGA) (OR = 15.4, P = 0.04). This was not confirmed in the analysis 301 
of the full REPROMETA sample set (GD: OR = 1.53, P = 0.14; SGA: OR = 1.18, P = 0.45). 302 
Additional suggestive association with GD was detected for the eSNP of PLEKHG1 (rs7738394 303 
OR = 0.05, P = 0.02), previously linked to the risk of preeclampsia (Gray et al., 2018). An eSNP 304 
modulating the expression of DNAJC15 was nominally associated with LGA (rs17553284; OR = 305 
0.05, P = 0.02). Interestingly, this variant has been reported as a top signal driving differentiated 306 
allele-specific expression between African and European populations (Tian et al., 2018).  307 
 308 
Placental eGenes exhibit broad functional portfolio 309 
According to the Human Protein Atlas, the identified 63 eGenes exhibited mostly mixed or 310 
ubiquitous gene and protein expression (Figure 1E). Only few genes are specifically expressed in 311 
the placenta, e.g. placental alkaline phosphatase ALPG and PSG7 (Table S6A-B). Based on the 312 
available literature evidence, the placental eGenes represent a broad portfolio of functional 313 
categories (Table 5). Almost 1/3 of eGenes were associated with general cellular functions 314 
[structure (n = 10, e.g. DCTN5, TTLL4) and transport (n = 10, e.g. AQP11, SLC27A6)]. About 10% 315 
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of genes are implicated in the immune function and immune-defense mechanisms that are critical 316 
in maintaining healthy pregnancy (n = 6, e.g. ERAP2, TRIM5). A functional enrichment analysis of 317 
eGenes highlighted 35 Gene Ontology (GO) categories (Table S6E). Interestingly, the most 318 
significantly enriched pathways were “ruffle membrane” (IFIT5, ADAM17, EPB41L5, FDR = 319 
1.81×10-2) contributing to the formation of motile cell surface and “ATPase activity, coupled” 320 
(ATP1A4, DDX11, RFC3, ATP8A1, PEX6; FDR = 2.88×10-2), critical for the active transport of 321 
molecules across cell membrane. Among the significantly (FDR<0.05) enriched GO categories 322 
there were also several pathways implicated in development, signaling and immune function. 323 
To obtain more potential functional insight, the identified eSNPs and eGenes were investigated for 324 
the overlap with association signals from published genome-wide association studies (GWAS). Six 325 
placental eSNPs have been directly associated with either blood metabolite levels (eSNP-eGenes 326 
pairs: rs2576452-TMC4, rs2041073-HEATR4 (Shin et al., 2014), rs6743376-IL36RN (Matteini et 327 
al., 2014)), risk to neurodegenerative diseases (rs10767971-PRRG4 (Latourelle et al., 2009), 328 
rs1129187-PEX6 (Jun et al., 2016)) or cancer (rs12309274-RAD52 (Zhang et al., 2014)) (Table 329 
S6F). These eSNP-eGene pairs have also been reported in GTEx with an effect in at least one other 330 
tissue. However, there was no statistically significant enrichment of GWAS hits among the 331 
identified eSNPs (6 of 199) compared to the overall proportion of GWAS SNPs (11,475 of 353,599) 332 
among the tested variants (χ-square test: OR=0.93 [0.41-2.09], P = 0.85). In total 58 of 63 of the 333 
eGenes were located within 100kb of various reported GWAS loci and 45 of them were assigned 334 
as the closest gene (Table S6G). However, due to the abundance of the GWAS associated genes 335 
(GWAS Catalog: 7433 of 11,733 genes tested in this study), this does not represent a significant 336 
enrichment (OR = 1.44 [0.84-2.50], P = 0.19). 337 
 338 
Validation of the eSNPs of ALPG, ERAP2 and ZSCAN9 using Taqman RT-qPCR 339 
From amongst the most significant eQTL signals, three (ZSCAN9 c.568+1990 C>T, ERAP2 340 
g.96984791 C>T, ALPG c.-318 G>A) were selected for validation experiments in an extended set 341 
of genotyped REPROMETA placental samples (n = 24/gene; see Methods; Table S2). In order to 342 
clarify potential eSNP effects on the neighboring genes, the analysis included also the ALPP gene 343 
that represents a duplicate locus to ALPG, and the ERAP1 and LNPEP genes flanking ERAP2 344 
(Figure 2). The eQTL effect on expression levels of ZSCAN9 (linear regression, additive model 345 
FDR = 3.6×10-11) and ERAP2 (FDR = 1.2×10-9) were robustly validated (Figure 3A, Table S8). 346 
The expression of ERAP1 and LNPEP was not modulated by ERAP2 g.96984791 C>T. Although 347 
in the validation dataset the effect of ALPG c.-318 G>A on ALPG expression level did not reach 348 
statistical significance (FDR = 0.18), the placentas carrying the minor A-allele exhibited a trend for 349 
increased ALPG and decreased ALPP expression (ALPP/ALPG ratio FDR = 1.2×10-2; Table S8). 350 
This observation requires further confirmation as there is a substantial difference between the 351 
expression levels of ALPP and ALPG that may have led to a statistical artefact. 352 
 353 
Suggestive association of the ALPG -318 G>A variant with newborn growth parameters in 354 
the REPROMETA study 355 
Association testing targeting the highlighted eSNPs near ZSCAN9, ERAP2 and ALPG was carried 356 
out with newborn parameters in the full REPROMETA sample set (n = 336) applying linear 357 
regression (Table 2). None of the tested associations resulted in a statistically significant outcome 358 
after correction for multiple testing. However, the ALPG c.-318 G>A exhibited a suggestive 359 
association under recessive model with the placental weight (AA-genotype effect -202g, nominal 360 
P = 9.3×10-3), as well as newborns’ chest circumference (-2.1cm, P = 3.2×10-3) and weight (-856g, 361 
P = 1.0×10-2) (Figure 3B; Table 6). Supportingly, previous studies have associated SNPs near 362 
ALPG with other anthropometric traits (height, waist and hip circumference) and implantation 363 
success (Figure 2C). Also, ZSCAN9 c.568+1990 C>T showed a nominal association with placental 364 
weight (TT-homozygotes: -54g, P = 4.4×10-2). 365 
The eSNPs were further tested for the association with the growth of the REPROMETA children 366 
during their first year of life. Based on the outcome of the association testing with birth parameters, 367 
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only the effect of homozygosity (recessive model) was applied. Six and 12 months old infants who 368 
were homozygous for the ALPG c.-318 A-allele had maintained lower weight compared to 369 
alternative genotype carriers (effect at 6 m: -1786g, nominal P = 1.3×10-2; 12 m: 1809g, P = 4.0×10-370 
2; Figure 3B). Also, their height remained lower during 6 postnatal months (effect -4.0cm, P = 371 
3.8×10-2), but it was caught up by the 1st birthday (P > 0.05). eSNPs of ERAP2 and ZSCAN9 showed 372 
no association with infant growth parameters. 373 
 374 
Meta-analysis of ALPG -318 G>A in the HAPPY PREGNANCY and ALSPAC cohort samples 375 
Association testing of the ALPG c.-318 G>A variant with the newborn anthropometric parameters 376 
was extended to two population-based cohorts HAPPY PREGNANCY (Estonia, n = 408) and 377 
ALSPAC (UK, n = 7669). The analysis in the individual cohorts and the meta-analysis combining 378 
the results from three studies did not replicate the initial associations with newborns’ and placental 379 
weight detected in the REPROMETA study (Table 7). However, only in the meta-analysis the 380 
association of ALPG c.-318 G>A with the newborn’s smaller head circumference reached nominal 381 
statistical significance (P = 0.042; effect -0.4 cm). The effect of the AA-genotype across the studies 382 
varied from -0.3 to -1.1 cm. 383 
 384 
Discussion  385 
Genetic variants modulating human placental gene expression have been understudied and so far 386 
only one genome-wide analysis of placental eQTLs has been published with no external 387 
independent validation (Peng et al., 2017). The current report represents the second study 388 
addressing specifically the landscape of placental cis-eQTLs, including experimental validation of 389 
selected top eSNP-eGene pairs and further exploration of their potential effect on human traits. The 390 
study identified 88 independent eSNP signals modulating the expression of 63 placental genes 391 
(termed as eGenes). Importantly, 50 loci overlapped with the placental eGene list from Peng et al., 392 
2017 and thus, can be claimed as robust placental eQTL signals to be explored further for their 393 
effect on placental function, fetal development, neonatal outcomes and postnatal disease risks 394 
(Table S6B). Unfortunately, the direction of these eSNP effects on the expression of the eGenes 395 
could not be compared among the studies as the reference allele was not equivocally stated in Peng 396 
et al., 2017.  397 
The current study identified additional 13 novel placental eGenes (Table 4). Among these, ZSCAN9 398 
represented an interesting novel locus modulated by several linked genetic variants and their highly 399 
significant eQTL effect was confirmed in experimental validation (Figure 3A, Table 3, Table 400 
S6A). A recent study reported that ZSCAN9 cis-eQTLs exhibit female specific effects on human X-401 
chromosomal methylation (Luijk et al., 2018). The ancestral A-allele of the variant rs1736891 was 402 
associated in cis with hypomethylated CpGs and high ZSCAN9 expression, and in trans with 403 
hypomethylation of the CpG islands near X-chromosomal genes variably escaping X-chromosomal 404 
inactivation. Also, in the current study, rs1736891 was detected among the top placental eQTLs 405 
associated with the ZSCAN9 transcript levels (Table S6A). The placenta is well known for its 406 
unusual hypomethylated epigenome and thus, the ZSCAN9 eSNPs may further contribute to the 407 
organ-specific enhanced expression of X-chromosomal genes that escape inactivation. As an 408 
additional interesting observation from the current study, worth to be followed-up in a larger cohort, 409 
was a potential effect of ZSCAN9 eQTLs to the risk of GD. Other interesting placental eSNP-eGene 410 
pairs are rs2871198-RBPJ and rs4370521-TCIM that have not been reported in GTEx. TCIM is a 411 
positive regulator of the Wnt/beta-catenin pathway (Jung et al., 2006) and RBPJ regulates the 412 
transcription of the Notch signaling pathway genes via recruitment of chromatin remodeling 413 
complexes to its targets (Han et al., 2002). Both pathways are critical in early human development. 414 
When comparing the current placental eSNP analysis outcome with the previous study (Peng et al., 415 
2017), the number of identified eGenes appears not as extensive (n = 63 vs 3218; Table S6C). 416 
However, in order to minimize false-positive predictions and to avoid spurious associations that are 417 
common in eQTL analysis (Huang et al., 2018), several stringent criteria for the eQTL detection 418 
were applied. One core difference between the two studies was in defining cis-eQTLs (±100kbp vs 419 
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±500kbp from gene), resulting in a five-fold smaller proportion of the genome targeted to the cis-420 
eQTL testing compared to the previous study (Peng et al., 2017). Another critical aspect was in 421 
applying a more conservative statistical significance threshold for claiming eQTL effect (5% vs 422 
10% FDR) that further reduced the number of robust claims. Thirdly, while this study relied only 423 
on directly genotyped genetic variants (n = 661,354), the previous placental eQTL analysis included 424 
also imputed SNPs (n = 5,748,854) that possibly increased the number of identified associations. 425 
Taken together, the careful study design facilitated the detection of high-confidence placental 426 
eSNPs, the majority of those were confirmed either by the independent dataset (Peng et al., 2017) 427 
or by the experimental approach. However, it has to be acknowledged that as the number of 428 
analyzed samples was modest (n = 40 vs 199 (Peng et al., 2017)), this possibly affected the study 429 
power.  430 
A critical role of placental function in fetal programming and its further impact on the health across 431 
the life span has been proposed already several years ago (Bonnin et al., 2011; Kwon and Kim, 432 
2017; Longtine and Nelson, 2011). As an example, the two haplotype variants of the placenta-433 
specific GH2 gene encoding placental growth hormone have been associated with the programming 434 
of adult height (Timasheva et al., 2013). In the current study, six eSNPs represented directly GWAS 435 
hits (6.8% of independent eQTL signals) and 45/63 eGenes were assigned as the closest gene to 436 
various GWAS SNPs for biomedical traits or diseases (Table S6G; Figure 2) However, we were 437 
not able to confirm a significant enrichment of GWAS top hits among the detected placental eSNP 438 
and eGenes that was reported by the previous placental eQTL study (Peng et al., 2017). 439 
Altered placental gene expression and the malfunctioning placenta are well-acknowledged risk 440 
factors for pregnancy complications and impaired fetal development (Ashar-Patel et al., 2017; 441 
Sifakis et al., 2018; Sõber et al., 2015, 2016; Sundrani et al., 2017). Our pilot analysis in the 442 
REPROMETA study detected a suggestive association of the AA-genotype of the eSNP ALPG c.-443 
318 (rs11678251) with the reduced weight of the placenta, newborn and infant until one year of age 444 
(Figure 3B; Table 6). ALPG represents one of the core trophectoderm (TE)-specific genes that 445 
drives the first cellular differentiation to inner cell mass and TE in early human development (Bai 446 
et al., 2012). However, the identified associations were not replicated in two independent and larger 447 
pregnancy cohorts of the HAPPY PREGNANCY and ALSPAC studies (Table 7). As the number 448 
of common genetic (and non-genetic) factors affecting anthropometric parameters is considered 449 
high and the effect sizes of individual variants are expected to be small (Tachmazidou et al., 2017; 450 
Wood et al., 2014), even a larger dataset than utilized in the current meta-analysis (n = 8,412) would 451 
be required to confirm or reject the preliminary findings.  452 
In summary, the study robustly demonstrated the role of genetic variation in driving the 453 
transcriptome profile of the human placenta and emphasized the importance to explore further the 454 
link between placental eQTLs, prenatal developmental programming and susceptibility to complex 455 
diseases. 456 
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Figure legends 493 
 494 
Figure 1. Overview of the placental cis-eQTL analysis outcome.  495 
(A) Manhattan plot representing the landscape of P-values from the discovery analysis. The 496 
association P-values for the three eSNPs-eGene pairs selected for validation experiments are shown 497 
for the discovery (green) and validation (blue) analysis. The red line indicates the statistical 498 
significance threshold (FDR 5%). (B) The proportion of eGene expression (R2) explained by the 499 
eSNPs detected in this study. (C) The expression levels of identified placental eGenes, shown in 500 
read counts from the RNA-Seq dataset.(Sõber et al., 2015) (D) The overlap of identified placental 501 
eGenes between the current study and Peng et al.(Peng et al., 2017) (E) Profile of mRNA and 502 
protein expression of the placental eGenes according to Human Protein Atlas 503 
(www.proteinatlas.org). 504 
 505 
Figure 2. Genomic regions surrounding the eSNP-eGene pairs selected for validation (A) 506 
ZSCAN9, (B) ERAP2 and (C) ALPG. 507 
Distances between the genes are drawn in approximate scale and the eGene of the region is 508 
highlighted with an increased font. eSNPs identified in the discovery study are shown above the 509 
genes. The eSNP chosen for experimental validation is boxed and its proxy SNPs in LD (r2>0.8) 510 
are shown in grey below the genes. The landscape of reported genetic associations with common 511 
traits and diseases demonstrated at the bottom part of each subfigure was derived from the GWAS 512 
catalogue and literature reports. The respective references are provided in Table S9. 513 
ALPG, alkaline phosphatase, germ cell; ALPI, alkaline phosphatase, intestinal; ALPP, alkaline 514 
phosphatase, placental; AS, ankylosing spondylitis; chr, chromosome; CID, chronic inflammatory 515 
disease; DIS3L2, DIS3 like 3'-5' exoribonuclease 2; ECEL1, endothelin converting enzyme like 1; 516 
eQTL, expression quantitative trait loci; ERAP1, Endoplasmic Reticulum Aminopeptidase 1; 517 
ERAP2, endoplasmic reticulum aminopeptidase 2; GWAS, genome-wide association study; IBD, 518 
inflammatory bowel disease; kb, kilobasepairs; LD, linkage disequilibrium; LNPEP, leucyl and 519 
cystinyl aminopeptidase; NKAPL, NFKB activating protein like; PE, preeclampsia; PGBD1, 520 
piggyBac transposable element derived 1; PsA, psoriatic arthritis; pulm. fn, pulmonary function; 521 
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SCLC, Squamous cell lung carcinoma; SDS, standard deviation score; UTI, urinary tract infection; 522 
ZKSCAN4, zinc finger with KRAB and SCAN domains 4; ZKSCAN8, zinc finger with KRAB and 523 
SCAN domains 8; ZSCAN9, zinc finger and SCAN domain containing 9; SCAN12, zinc finger and 524 
SCAN domain containing 12; ZSCAN16, zinc finger and SCAN domain containing 16; ZSCAN26, 525 
zinc finger and SCAN domain containing 26; ZSCAN31, zinc finger and SCAN domain containing 526 
31; 527 
 528 
Figure 3. Experimental validation and genetic association testing with newborn parameters.  529 
(A) Comparative effect sizes from the RNA-Seq discovery and Taqman RT qPCR experiments for 530 
the eSNP-eGene associations selected for the experimental validation. For the estimation of fold 531 
changes, median expression level in the placentas with the major homozygote genotype was 532 
considered as the reference. Statistical analysis for association testing was performed under linear 533 
regression using additive model adjusted by the newborn sex, pregnancy complication group and 534 
labor activity. As the validation dataset was not matched for gestational age at delivery, this 535 
parameter was additionally incorporated as a covariate in the validation step. The shown P-values 536 
have been corrected multiple testing using FDR method. n, number of samples 537 
(B) Effect of the ALPG c.-318 G>A (rs11678251) eSNP on the offspring growth parameters at birth 538 
and during infancy in the REPROMETA dataset. The data was available for 336 newborns at 539 
delivery, and their follow-up data at the of 6 (n=233) and 12 (n=216) months of age. Genetic 540 
association testing was performed using linear regression under recessive model adjusted by fetal 541 
sex. In testing the newborn parameters, gestational age at delivery was used as an additional 542 
covariate. The obtained nominal P-values <0.05 were considered as supportive for the trend of a 543 
tested association. Beta values reflect the estimated effect of the AA-homozygosity on the tested 544 
parameter. 545 
546 
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Table 1. Maternal and newborn data of the term placentas utilized cis-eQTL discovery analysis 547 
(n=40) 548 
 Parameter Unit eQTL analysis samples 
Maternal age year 28.5 [18-39] 
Gestational age at delivery day 274.0 [260-284] 
Newborn birth weight gram 3587 [2004-4986] 
Newborn length cm 50.2 [45-55] 
Placental weight gram  584.0 [200-1060] 
Newborn sex: female/male n 21/19 
Delivery mode: EmCS/ECS/Vag n [%] 9/12/19 [22.5%/ 30.0%/47.5%] 
Labor activity: no/yes/NA n [%] 19/20/1 [47.5%/ 50.0%/2.5%] 
Pregnancy complications n  32 [80%] 
PE, GDM, SGA, LGA: 8 each 
All cases were recruited, clinical data and placental tissue was collected in the framework of the 549 
REPROMETA study at the Women’s Clinic of Tartu University Hospital, Estonia. Detailed information on 550 
this sample set and respective the placental RNA-Seq data is provided in Supplementary Methods and 551 
original references (Reiman et al., 2017; Sõber et al., 2015). Data is given as mean [minimum-maximum] 552 
unless indicated differently. 553 
ECS, elective cesarean section; EmCS, emergency cesarean section; GD, gestational diabetes; LGA, large-554 
for-gestational age newborn; NA, not available; PE, preeclampsia; SGA, small-for-gestational age newborn; 555 
Vag, vaginal delivery. 556 
  557 
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Table 2. REPROMETA, HAPPY PREGNANCY and ALSPAC datasets utilized in the genetic 558 
association testing with newborn traits 559 
 Parameter REPROMETA 
(n=336) 
HAPPY 
PREGNANCY 
(n=408) 
ALSPAC (n=7669) 
Gestational age at delivery  273.4 [196-299] days 271.9 [167-294] days 39.5 [25-47] weeks 
Newborn sex (F/M) 170/166 204/204 3732/3937 
Placental weight (g) 585.1 [190-1122] 539.4 [190-1132] 657.1 [240-1260]a 
Birth weight (g) 3545 [990-5740] 3127.1 [560-4418] 3448.8 [645-5640] 
Birth length (cm) 49.9 [35-57] 49.0 [29.5-56] 50.8 [34-62] 
Head circumference (cm) 34.8 [26-40] 34.2 [22-38] 34.9 [20.3-54] 
Chest circumference (cm) 34 [21-43] 32.8 [22.5-37] NA 
Preeclampsia (n [%]) 43 [12.8%] 8 [2.0%] 150 [2.0%] 
Gestational diabetes (n [%]) 41 [12.2%] 10 [2.5%] 37 [0.5%] 
SGA newborn (n [%])b 65 [19.3%] 158 [38.7%] 771 [10.1%] 
LGA newborn (n [%]) 83 [24.7%] 4 [1.0%] 764 [10.0%] 
Maternal age (yrs) 28.7 [16-43] 28.9 [15.8-47.2] 28.6 [15-44] 
Maternal height (cm) 167.1 [150-185] 166.4 [150-186] 164.2 [143.5-188.3]a 
Maternal pre-pregnancy 
weight (kg) 
67.9 [43-142] 63.3 [40-106] 60.9 [31.6-141.6] 
Gestational weight gain (kg) 15.5 [(-3)-40] 12.1 [1.2-28] 12.6 [-6.7-37.8] 
Maternal smoking: no/yes 
(n [%]) 
306/21 [91.1%/6.3%] 385/23 [94.4%/5.6%] 5845/1595 
[78.6%/21.4%] 
a data were available for fewer than half of the samples. b SGA includes preeclampsia and preterm cases. 560 
Data is given as mean [minimum-maximum] unless indicated differently. REPROMETA clinical cases were 561 
recruited in 2006-2011 and HAPPY PREGNANCY cohort cases in 2013-2015 at the Women’s Clinic of 562 
Tartu University Hospital, Estonia. ALSPAC cohort cases were recruited in 1991-1992 in Bristol area, 563 
United Kingdom. Detailed information on each study is provided in Materials and Methods. LGA, large-564 
for-gestational age newborn; NA, not available; SGA, small-for-gestational age newborn.  565 
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Table 3. Top 10 protein coding eGenes from the discovery placental cis-eQTL analysis. 
Lead eQTL 
chr:position 
Alleles 
MAF 
eGene 
(n, 
eQTLs) 
P-value 
P (FDR)a 
Read countb 
(AA) 
Read count 
(Aa) 
Read count 
(aa) 
 fcc 
(Aa) 
fc 
(aa) 
R2 for eQTL 
and gene 
expressiond 
eQTL in 
GTExe 
mRNA/ Proteinf Peng 
et al 
rs2249563 
4:39453758 
G>A 
21% 
RPL9 
(3) 
1.09×10-11 
9.68×10-7 
239  
(180,317) 
392  
(304,454) 
555  
(singleton) 
1.64 2.32 0.768 All tissues All/All Y 
rs1150707 
6:28229827g 
C>T 
30% 
ZSCAN9g 
(23) 
1.17×10-11 
9.68×10-7 
131  
(92,230) 
475  
(267,686) 
596  
(493,644) 
3.62 4.54 0.767 skin All/ Mixed N 
rs10044354 
5:96984791g 
C>T 
41% 
ERAP2g 
(11) 
8.63×10-11 
5.69×10-6 
470 
(339,1182) 
1512  
(813,2354) 
2189  
(1252,2602) 
3.22 4.65 0.737 All tissues Mixed/ Mixed Y 
rs10743750 
12:31087400 
C>T 
28% 
DDX11 
(2) 
3.49×10-10 
1.92×10-5 
503  
(326,700) 
355 
 (299,502) 
182  
(145,252) 
0.71 0.36 0.713 All tissues All/ Mixed Y 
rs7738394 
6:150685788 
T>C 
30% 
PLEKHG1 
(1) 
4.34×10-9 
1.43×10-4 
2079  
(1602,2393) 
1617  
(1039,1784) 
825  
(755,895) 
0.78 0.40 0.665 testis, 
esophagus 
Enhanced 
(testis)/All 
Y 
rs7252798 
19:21734730 
C>T 
46% 
ZNF100 
(1) 
4.57×10-9 
1.44×10-4 
187  
(119,280) 
310  
(201,480) 
427  
(304,588) 
1.66 2.28 0.664 Most tissues Mixed/NA Y 
rs567637 
16:84500760 
G>A 
48% 
TLDC1  
(5) 
1.36×10-8 
4.07×10-4 
1241  
(1085,1837) 
1886  
(1157,2722) 
2465  
(1870,2956) 
1.52 1.99 0.640 esophagus Mixed/ Mixed N 
rs10865489 
2:88147373 
T>G 
31% 
THNSL2 
(2) 
1.66×10-8 
4.57×10-4 
577  
(351,724) 
319  
(217,622) 
171  
(141,191) 
0.55 0.30 0.636 All tissues Enhanced 
(parathyroid)/ Mixed 
Y 
rs2612520 
4:42645785 
G>T 
38% 
ATP8A1 
(1) 
2.86×10-8 
7.55×10-4 
60  
(25,263) 
281  
(42,816) 
479  
(280,821) 
4.64 7.92 0.623 10 tissues 
adipose, 
breast etc. 
Enhanced 
(parathyroid)/ Mixed 
Y 
rs11678251 
2:232406577g 
 G>A 
11% 
ALPGg 
(4) 
7.62×10-8 
1.52×10-3 
372  
(33,834) 
1336  
(579,1708) 
NA 3.60 NA 0.600 colon, lung Enhanced (fallopian 
tube)/ Placenta 
Y 
eQTL association testing was implemented in Matrix eQTL (Shabalin, 2012) using linear regression adjusted by the pregnancy outcome (normal term or PE, GD, 
SGA, LGA pregnancy), labor activity and newborn sex  
a False discovery rate was calculated according to Benjamini and Hochberg method, b normalized read count, median (min, max); c fold change from median 
normalized read count of major homozygotes, d fraction of gene expression variation explained by the eQTL genotypes (range 0- 1), e GTEx reports eQTL data for 
48 tissues, excluding placenta (https://gtexportal.org); f the Human Protein Atlas (https://www.proteinatlas.org/); g selected for validation 
ALPG, Alkaline phosphatase, germ cell; chr, chromosome; ATP8A1, ATPase phospholipid transporting 8A1; DDX11, DEAD/H-box helicase 11; DNAJC15, DnaJ 
heat shock protein family (Hsp40) member C15; ERAP2, Endoplasmic reticulum aminopeptidase 2; fc, fold change; MAF, minor allele frequency; NA., not available; 
PLEKHG1, pleckstrin homology and RhoGEF domain containing G1; ptg, parathyroid gland; RPL9, ribosomal protein L9; THNSL2, threonine synthase like 2; 
TLDC1, TBC/LysM-associated domain containing 1; ZNF100, zinc finger protein 100; ZSCAN9, Zinc finger and SCAN domain containing 9.  
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Table 4. Characteristics of 13 novel placental eGenes, identified in the current study. 
Lead cis-eSNP 
Chr: Position 
Alleles 
MAF 
eGene  
(number of 
cis-eSNPs) 
P-value  
P (FDR)a 
Read countb  Fold changec R2 for 
eQTL and 
gene 
expressiond 
Biological function mRNA/ 
Proteine 
GTExf 
Maj 
hom 
Het 
 
Min 
hom 
Het Min 
hom 
rs1150707 
chr6:28229827 
T<C 
0.30 
ZSCAN9 
(23) 
1.17×10-11 
9.68×10-7 
131 475 596 3.62 4.54 0.77 Transcription factorg All/  
Mixed 
Y 
rs1132812 
chr16:30186830 
A<G 
0.45 
SMG1P5 
(2) 
2.93×10-9 
1.02×10-4 
145 440 610 3.03 4.21 0.67 Pseudogene NA/  
NA 
Y 
rs567637 
chr16:84500760 
A<G 
0.48 
TLDC1 
(5) 
1.36×10-8 
4.07×10-4 
1242 1886 2465 1.52 1.99 0.64 Cell proliferation (Nguyen et 
al., 2018)  
Mixed/  
All 
Y 
rs9320475 
chr6:113922342 
T<C 
0.21 
FO393415.1 
(1) 
5.34×10-8 
1.26×10-3 
91 241 255 2.65 2.80 0.61 Pseudogene NA/  
NA 
Y 
rs3810756 
chrX:119417694 
T<C 
0.05 
SLC25A43 
(2) 
3.67×10-7 
4.48×10-3 
192 131 123 0.68 0.64 0.56 Mitochondrial transporter 
(Gabrielson et al., 2016) 
Mixed/ 
Enhanced 
(Liver) 
Y 
rs10767971 
chr11:32874118 
T<C 
0.35 
PRRG4 
(4) 
5.64×10-7 
6.45×10-3 
1023 1400 1923 1.37 1.89 0.55 Neuronal regulation (Justice et 
al., 2017) 
Mixed/ 
Mixed 
Y 
rs1053846 
chr1:39757468 
G<T 
0.21 
PPIE 
(3) 
1.29×10-6 
1.24×10-2 
199 306 394 1.53 1.98 0.52 Splicing (Chanarat and Sträßer, 
2013) 
All/  
All 
Y 
rs2871198 
chr4:26290933 
C<T 
0.33 
RBPJ 
(1) 
1.91×10-6 
1.68×10-2 
2663 3105 3703 1.17 1.39 0.51 Transcriptional regulation (Han 
et al., 2002) 
All/  
NA 
N 
rs7046565 
chr9:109539940 
C<T 
0.43 
YBX1P6 
(1) 
6.26×10-6 
3.22×10-2 
32 156 164 4.87 5.15 0.48 Pseudogene NA/  
NA 
Y 
rs10869496 
chr9:75085168 
A<C 
0.36 
NMRK1 
(1) 
7.20×10-6 
3.52×10-2 
433 353 261 0.82 0.60 0.47 NAD metabolism (Bieganowski 
and Brenner, 2004) 
All/ 
Mixed 
Y 
rs4370521 
chr8:40111873 
G<A 
0.33 
TCIM 
(1) 
7.63×10-6 
3.62×10-2 
300 473 631 1.58 2.10 0.47 Cell cycle regulator (Jung et al., 
2006) 
Mixed/ 
Mixed 
N 
rs7850758 
chr9:137293773 
G<A 
0.06 
TPRN 
(1) 
1.29×10-5 
4.69×10-2 
218 304 NA 1.40 NA 0.45 Hearing (Li et al., 2010) All/ 
All 
N 
rs11692913 
chr2:39853203 
A<G 
0.35 
THUMPD2 
(1) 
1.44×10-5 
4.77×10-2 
217 230 281 1.06 1.29 0.45 tRNA metabolismg Mixed/ 
Mixed 
N 
eQTLs were tested using linear regression adjusted by the pregnancy outcome (normal term or PE, GD, SGA, LGA pregnancy), labor activity and newborn sex 
a False discovery rate was calculated according to Benjamini and Hochberg method; b normalized read count, median (min,max); c fold change compared to median 
normalized read count of major homozygotes; d fraction of gene expression variation explained by the cis-eSNP genotypes (scale 0-1); e data from the Human Protein 
Atlas (https://www.proteinatlas.org/); f eQTL identified in GTEx for at least one tissue; g predicted annotation from UniprotKB. Maj hom, major homozygote; Het, 
heterozygote; Min hom, Minor homozygote; NMRK1, nicotinamide riboside kinase 1; PPIE, peptidylprolyl isomerase E; PRRG4, proline rich and Gla domain 4; 
RBPJ, Recombination signal binding protein for immunoglobulin kappa J region; SLC25A43, solute carrier family 25 member 43; SMG1P5, SMG1 pseudogene 5; 
TCIM, transcriptional and immune response regulator; THUMPD2, THUMP domain containing 2; TLDC1, TBC/LysM-associated domain containing 1; TPRN, 
taperin; YBX1P6, Y-box binding protein 1 pseudogene 6; ZSCAN9, Zinc finger and SCAN domain containing 9 
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Table 5. Identified eGenes classified by their main functional category. 1 
Function n Genes 
Cellular transport 10 AQP11, ATP1A4, ATP8A1, CNIH4, HEATR5A, SLC25A43, 
SLC27A6, SLC44A1, SNX25, TMC4, DNAJC15 
Cell structure 10 CEP128, CEP72, DCTN5, EPB41L5, FAM118A, HEATR4, 
LYPD5, NEO1, PEX6, TPRN, TSGA10, TTLL4 
Transcription 7 TCIM, TRIM66, RBPJ, ZNF100, ZNF266, ZNF749, ZSCAN9 
Immunity/defense 6 CBLB, ERAP2, IFIT5, IL36RN, PSG7, TRIM5 
Enzymatic activity 5 ALPG, ATG10, IP6K3, NMRK1, THNSL2 
DNA replication/repair 4 DDX11, RAD52, RFC3, CYREN 
Translational regulation 
and protein modification 
4 SPSB2, RPL9, PPIE, THUMPD2 
Signaling 4 ADAM17, GLS, PLEKHG1, PRRG4 
Cellular proliferation and 
differentiation 
2 TLDC1, SLFN5 
Other 4 ABHD11, PSMD5, THNSL2, WDR91 
Unclassified 1 HEATR5A 
Pseudogene 5 FO393415, GUCY1B2, YBX1P6, SMG1P5, HTR7P1 
Genes were grouped according to data retrieved from UniProtKB/Swiss-Prot database, Entrez gene database 2 
and/or literature.  3 
  4 
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Table 6. Association testing of validated eQTL with newborn traits in the REPROMETA study 5 
(n=335). 6 
Tested 
parameter 
and genetic 
model 
ALPG  ERAP2  ZSCAN9  
 G>A rs11678251 C>T rs10044354 C>T rs1150707 
Effect (SE) P-value Effect (SE) P-value Effect (SE) P-value 
Placental weight (grams) 
Additive -48 (19) 1.0×10-2 6 (12) 6.1×10-1 -12 (13) 3.4×10-1 
Recessive -202 (77) 9.0×10-3 -3 (21) 8.9×10-1 -54 (27) 4.4×10-2 
Birth weight (grams) 
Additive -161 (81) 4.7×10-2 42 (50) 4.1×10-1 -59 (55) 2.8×10-1 
Recessive -856 (332) 1.0×10-2 64 (92) 4.9×10-1 -145 (116) 2.1×10-1 
Birth length (cm) 
Additive -0.4 (0.3) 1.4×10-1 0.2 (0.2) 3.0×10-1 -0.2 (0.2) 4.3×10-1 
Recessive -1.9 (1.2) 1.2×10-1 0.4 (0.3) 2.7×10-1 -0.4 (0.4) 4.1×10-1 
Head circumference at birth (cm) 
Additive -0.3 (0.2) 2.0×10-1 0.1 (0.1) 3.4×10-1 -0.3 (0.1) 7.2×10-2 
Recessive -1.1 (0.9) 2.0×10-1 0.2 (0.2) 3.4×10-1 -0.5 (0.3) 1.2×10-1 
Chest circumference at birth (cm) 
Additive -0.3 (0.2)  1.6×10-1 0.3 (0.2) 1.0×10-1 -0.1 (0.2) 5.1×10-1 
Recessive -2.1 (0.7)  3.2×10-3 0.3 (0.4) 3.7×10-1 -0.4 (0.4) 3.2×10-1 
At 6 months of age (only recessive model)a 
Weight -1786 (711) 1.3×10-2 120 (206) 5.6×10-1 169 (263) 5.2×10-1 
Height -4.0 (1.9) 3.8×10-2 0.4 (0.6) 5.0×10-1 0.2 (0.7) 8.4×10-1 
At 12 months of age (only recessive model)a 
Weight -1809 (876) 4.0×10-2 -85 (262) 7.5×10-1 45.2 (330.3) 8.9×10-1 
Height -3.6 (2.2) 9.9×10-2 0.5 (0.7) 4.2×10-1 0.27 (0.82) 7.4×10-1 
Association testing with birth parameters was implemented using linear regression analysis under additive 7 
and recessive model, adjusted by newborn sex and gestational as covariates. The obtained nominal P-values 8 
<0.05 (in bold) were considered as supportive for the trend of a tested association. The Bonferroni corrected 9 
statistical significance level was estimated P<1.2×10-3. 10 
a Postnatal growth data was available for 231 children (121 girls and 110 boys). Based on the outcome of the 11 
primary analysis with birth parameters, only recessive model (sex-adjusted) was applied for association 12 
testing with postnatal growth.  13 
ALPG, Alkaline phosphatase, germ cell; ERAP2, Endoplasmic reticulum aminopeptidase 2; ZSCAN9, Zinc 14 
finger and SCAN domain containing 9. 15 
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Table 7. Meta-analysis of the genetic association testing of the ALPG c.-318 G>A (rs11678251) with newborn traits in the REPROMETA, HAPPY 16 
PREGNANCY and ALSPAC studies. 17 
Newborn 
parameter 
REPROMETA   HAPPY 
PREGNANCY 
  ALSPAC   Meta-analysis 
Effect (SE) P-value n Effect (SE) P-value  n Effect (SE) P-value n Effect (SE) P-value n 
All newborns  
           
Birth weight (g) -856 (332) 1.0×10-2 335 -199 (164) 2.3×10-1 408 -61 (57) 2.9×10-1 7669 -96 (53) 7.2×10-2 8412 
Placental weight (g) -202 (77) 9.0×10-3 331 -19 (46) 6.8×10-1 406 29 (27) 2.9×10-1 3123 -2 (22) 9.2×10-1 3860 
Birth length (cm) -1.9 (1.2) 1.2×10-1 330 -0.7 (0.7) 3.3×10-1 390 -0.3 (0.3) 3.6×10-1 6077 -0.4 (0.3) 1.2×10-1 6797 
Head circumference 
(cm) 
-1.1 (0.9) 2.0×10-1 328 -0.8 (0.5) 1.1×10-1 343 -0.3 (0.2) 1.8×10-1 6159 -0.4 (0.2) 4.2×10-2 6830 
Chest circumference 
(cm) 
-3.53 (1.25) 5.1×10-3 325 -0.86 (0.7) 2.2×10-1 337 NA NA NA -1.49 (0.61) 1.5×10-2 662 
Linear regression analysis under recessive model adjusted by covariates newborn sex and gestational age (in days for REPROMETA and HAPPY PREGNANCY, 18 
in weeks for ALSPAC) was applied. The obtained nominal P-values <0.05 (in bold) were considered as a suggestive association. Bonferroni significance level 19 
corrected for the number of individual tests was calculated 0.05/14=3.6×10-3. ALPG, alkaline phosphatase, germ cell; NA, not available; SE, standard error 20 
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